Goldberg Andrew D. 4

What Happened

• Andrew D. Goldberg, a non‑employee director of Tarsus Pharmaceuticals (TARS), had 2,954 shares issued on June 12, 2026 upon settlement of vested restricted stock units (RSUs). The Form 4 records an acquisition of 2,954 shares (derivative conversion) and a corresponding derivative disposition of 2,954 shares at $0.00. The filing was submitted on June 16, 2026.

Key Details

• Transaction date: June 12, 2026; Form 4 filed: June 16, 2026 (timely).
• Reported items: Exercise/conversion of derivative (code M) — 2,954 shares acquired; matching derivative disposition of 2,954 shares at $0.00.
• Price/consideration: No purchase price reported (shares issued upon RSU settlement).
• Shares owned after transaction: Not specified in the filing.
• Footnotes: RSUs represent contingent rights to receive one share each; these RSUs were granted on June 12, 2025 in connection with service as a non‑employee director and vested in full on the one‑year anniversary (per the filing).

Context

• This was an RSU settlement (award conversion to common stock), a routine form of director compensation rather than an open‑market purchase or sale. The filing records both the issuance (acquisition) and a $0.00 derivative disposition; the Form does not provide an economic explanation for the disposition. Such award settlements are not direct buy/sell signals but do increase insider ownership when shares remain outstanding.